Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Protagonist Therapeutics (PTGX) Accumulated Depreciation & Amortization (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 18.19% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 18.19% year-over-year, with the annual reading at $8.3 million for FY2025, 18.19% up from the prior year.
  • Accumulated Depreciation & Amortization hit $8.3 million in Q4 2025 for Protagonist Therapeutics, up from $7.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.3 million in Q4 2025 to a low of $4.5 million in Q1 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $6.4 million across 5 years, with a median of $6.7 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 21.37% in 2023 and later fell 4.58% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $5.8 million in 2021, then increased by 15.0% to $6.7 million in 2022, then rose by 10.66% to $7.4 million in 2023, then dropped by 4.58% to $7.0 million in 2024, then grew by 18.19% to $8.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for PTGX at $8.3 million in Q4 2025, $7.9 million in Q3 2025, and $7.6 million in Q2 2025.